Patent number: 7960434
Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.
Type:
Grant
Filed:
May 21, 2007
Date of Patent:
June 14, 2011
Assignees:
University of South Florida, University of Central Florida Research Foundation, Inc., H. Lee Moffitt Cancer Center & Research Institute
Inventors:
James Turkson, Said M. Sebti, Wayne Guida, Man Lun Yip, Nicholas J. Lawrence, Harshani Lawrence, Benjamin Greedy